Skip to main content

Human CXCL9/MIG Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF392

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF392

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

ELISA Detection (Matched Antibody Pair), Western Blot

Cited:

ELISA Development, Luminex Development

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant human CXCL9/MIG (R&D Systems, Catalog # 392-MG)
Thr23-Thr125
Accession # Q07325

Specificity

Detects human CXCL9/MIG in ELISAs and Western blots. In sandwich immunoassays, less than 0.2% cross-reactivity with recombinant human (rh) IL‑12, recombinant mouse CXCL9/MIG, and rhIL‑8 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Human CXCL9/MIG Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human CXCL9/MIG (Catalog # 392-MG)

Human CXCL9/MIG Sandwich Immunoassay

ELISA Detection (Matched Antibody Pair)
Recommended Concentration: 0.1-0.4 µg/mL
Use in combination with these reagents:
  • Detection Reagent: Human CXCL9/MIG Antibody (Catalog # MAB392)
  • Standard: Recombinant Human CXCL9/MIG Protein (Catalog # 392-MG)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using BAF392 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL9/MIG

CXCL9, a member of the alpha subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9 was subsequently cloned using mouse MIG cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma. CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid residue precursor protein with a 22 amino acid residue signal peptide that is cleaved to yield a 103 amino acid residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. The carboxy-terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy-terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP‑10 has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

References

  1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
  2. Liao, F. et al. (1995) J. Exp. Med. 182:1301.
  3. Vanguri, P. (1995) J. Neuroimmunol. 56:35.

Alternate Names

MIG

Entrez Gene IDs

4283 (Human); 17329 (Mouse); 246759 (Rat)

Gene Symbol

CXCL9

UniProt

Additional CXCL9/MIG Products

Product Documents for Human CXCL9/MIG Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CXCL9/MIG Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...